[Lieyun Network Beijing] reported on January 29
Recently, Luzhu Biologics, a developer of human vaccines and biological products, announced the completion of a 120 million yuan B+ round of financing, which was jointly invested by Xuanhong Fund, Mingfeng Capital, Shaanxi Financial Holdings/New Era Capital, Mingsheng Capital and other institutions and strategic parties.
The financing is a new round of financing that was quickly completed after receiving the 350 million yuan B round of financing led by CCB International in August 2021 and co-invested by two A+H listed companies Tigermed and Lizhu Pharmaceutical, which will greatly accelerate the company's independent innovation and restructuring of the clinical trial research of the herpes zoster vaccine LZ901 in China and the United States, as well as the treatment of recurrent/refractory B-cell leukemia (ALL) and the treatment of recurrent/refractory B-cell non-Hodgkin lymphoma (NHL) Clinical phase I/II study of bifunctional antibody CD19-CD3.
It is understood that after this round of financing, Luzhu Bio will more quickly promote the construction of Zhuhai industrialization base and launch the IPO plan in a timely manner.
Kong Jian, founder, CEO and chief scientist of Luzhu Biotech, said: "I am very grateful to the B+ round investors for their high recognition of the company's innovative products and continuous research and development capabilities, and for completing the investment decision in a short period of time. Luzhu Biological R&D team has been engaged in the research and development of innovative vaccines and antibody drugs for more than 20 years, insisting on solving the rigid needs of disease prevention and treatment, making innovative vaccines and drugs to meet the unmet social needs, and hoping that our drugs and vaccines can become excellent products that benefit patients and ordinary people after undergoing rigorous clinical research. ”
Ms. Jiang Xianmin, co-founder and chief medical officer of Luzhu Biology, said: "The company's core product recombinant shingles vaccine has started clinical trials and is progressing rapidly, hoping that the vaccine can bring a good experience of preventing shingles for the elderly; at present, the company's clinical research on many drugs and vaccines is steadily advancing, and I believe that our company will have more products to benefit the majority of people and patients in the future." ”
The investors in this round said: "The team led by Teacher Kong Jian and Teacher Jiang Xianmin is very pragmatic and has strong implementation ability, which we recognize very much. Luzhu Bio's core team has solid technology, has a very rich successful experience in the vaccine industry, Luzhu Bio's recombinant herpes zoster vaccine has been declared to the US FDA for clinical research, and is the first enterprise in China to apply for vaccine clinical research in the United States. We are excited to join forces to invest together to help businesses thrive." ”
Beijing Luzhu Biotechnology Co., Ltd. was established in November 2001, the co-founders of the company are Kong Jian, a former researcher at the Beijing Institute of Biological Products, Jiang Xianmin and Zhang Yanping, associate researchers. In view of the fact that there was no vaccine available for the prevention of epidemic meningococcal meningitis infection in children under 2 years of age at home and abroad at that time, combined with the polysaccharide protein coupling technology that had been mastered, a variety of bacterial polysaccharide protein conjugate vaccines and high-purity low-pyrogen polysaccharide vaccines (both of which have been transferred to the listed company Zhifei Biological, stock code: 300122. SZ), Luzhu Bio is the first company in the world to develop a group C meningococcal polysaccharide conjugate vaccine. The company has applied for 12 innovative drug invention patents (2 PCT) and 5 authorized invention patents in the past 5 years; in the past 5 years, it has obtained 2 clinical approvals for monoclonal antibody biosimilars, 1 clinical approval for bispecific antibodies, 1 clinical approval for inactivated viral vaccines, and 1 approval for recombinant viral protein vaccines.
In November 2018, Luzhu Biotech established a wholly-owned subsidiary, Luzhu Biopharmaceutical (Zhuhai) Co., Ltd., covering an area of 105 acres, focusing on the research and development and production of high-end human vaccines and biological drugs, and is committed to building a first-class biopharmaceutical industrialization base with high international standards.